Skip to content

Research on Key Technologies for Pathogenesis, Objective Diagnosis, and Precise Classification of Common Otogenic Vertigo

Research on Key Technologies for Pathogenesis, Objective Diagnosis, and Precise Classification of Common Otogenic Vertigo

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121134
Enrollment
Unknown
Registered
2026-03-26
Start date
2026-03-26
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Otogenic Vertigo

Interventions

BPPV :None
Meniere's disease :None
Vestibular Neuritis:None
Bilateral Vestibulopathy and Senile Vestibulopathy:None

Sponsors

Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Informed Consent: The patient or their legal representative voluntarily signs the informed consent form and is willing to cooperate with clinical examinations, sample collection, and long-term follow-up. 2. Meet the typical age characteristics for various diseases, generally 18-80 years old. 3. Diagnostic criteria for various diseases: (1) Benign Paroxysmal Positional Vertigo (BPPV): Diagnosis conforms to the "Barany Society BPPV Diagnostic Criteria": short-term vertigo (=2 times within the past 6 months). Positional tests and vestibular function examinations can be performed. (2) Ménière's Disease (MD): Diagnosis conforms to the "Barany Society MD Diagnostic Criteria": at least 2 episodes of persistent vertigo (each >=20 minutes); fluctuating hearing loss (pure tone audiometry showing low-frequency or full-frequency hearing loss); tinnitus and/or a feeling of ear fullness. (3) Vestibular Neuritis (VN): Diagnosis conforms to acute onset, persistent vertigo >=24 hours, accompanied by nausea and vomiting, without hearing loss or with mild hearing loss; cold and hot tests or video head impulse test (vHIT) indicating unilateral vestibular dysfunction; central lesions excluded (e.g., negative brain MRI). (4) Bilateral Vestibulopathy: Diagnosis conforms to chronic progressive balance disorder, unsteady gait, worsened in darkness; bilateral vestibular function tests (e.g., vestibular-evoked myogenic potentials, vHIT) showing bilateral dysfunction; other causes excluded (e.g., drug toxicity, hereditary diseases). (5) Age-related Vestibular Dysfunction: Diagnosis conforms to age >=60 years; chronic balance disorder, with or without vertigo, duration >=3 months; vestibular function tests showing bilateral or unilateral dysfunction, with other clear causes excluded (e.g., cerebrovascular disease, tumors).

Exclusion criteria

Exclusion criteria: 1. Severe systemic diseases: Diseases such as hepatic or renal insufficiency, severe cardiovascular diseases, or malignant tumors that may affect study outcomes or prognosis. 2. Causes of central vertigo: Etiologies including stroke, multiple sclerosis, intracranial tumors, etc. 3. Recent medication effects: Use of immunosuppressants, glucocorticoids, antiviral drugs (only for vestibular neuritis [VN] patients), or metabolism-affecting drugs (e.g., hypoglycemic agents, lipid-lowering agents) within the past 1 month. 4. Pregnant or lactating women. 5. Cognitive impairment or mental disorders: Inability to cooperate with examinations and follow-up. (1) BPPV: Complicated by severe cervical spondylosis or a history of neck trauma (within the past 3 months). (2) MD: Concurrent severe autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis). (3) VN: Concurrent herpes zoster virus infection, HIV infection, or a history of other confirmed viral infections. (4) Bilateral vestibular disease / Senile vestibular disease: Concurrent diabetes, thyroid dysfunction, or severe vitamin D deficiency (<10 ng/mL).

Design outcomes

Primary

MeasureTime frame
Metabolomics parameters indicator;

Secondary

MeasureTime frame
Immunomics indicator;

Countries

China

Contacts

Public ContactLi Huawei

Eye and ENT Hospital of Fudan University

hwli@shmu.edu.cn+86 189 1778 5659

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026